Porges: Gilead’s hep C bash is winding down and it doesn’t have a cure for the hangover
Leerink analyst Geoffrey Porges has often been willing to prescribe harsh medicine to big biopharma players that need to wake up fast. This morning, he took a hard poke at a slumbering Gilead, which he believes is in for a wicked fall as its monumental hep C franchise faces rapidly dropping patient numbers.
Porges downgraded the stock $GILD – which dropped 1.5% this morning – after he turned openly bearish on hep C revenue forecasts. The analyst writes:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.